Photodynamic therapy combined with a cysteine proteinase inhibitor synergistically decrease VEGF production and promote tumour necrosis in a rat mammary carcinoma

Cell Proliferation

Volumn 40, Issue 1, 2007, Pages 38-49

  Zsebik, B ^a,b   Symonowicz, K ^b   Saleh, Y ^b   Ziolkowski, P ^b   Bronowicz, A ^b   Vereb, G ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORIN E6; CHLORINE DERIVATIVE; CYSTATIN; CYSTEINE PROTEINASE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; BREAST CARCINOMA; CAPILLARY BLOOD; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; NONHUMAN; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; RAT; TUMOR NECROSIS; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANIMALS; CARCINOMA; CYSTATINS; CYSTEINE PROTEINASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; NECROSIS; NEOPLASM TRANSPLANTATION; PHOTOCHEMOTHERAPY; RATS; RATS, WISTAR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 33846193227     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/j.1365-2184.2007.00420.x     Document Type: Article

References (36)

1. Buck MR, Karustis DG, Day NA, Honn KV, Sloane BF (1992) Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem. J. 282, 273-278.
2. Caruso JA, Mathieu PA, Joiakim A, Leeson B, Kessel D, Sloane BF, Reiners JJ Jr (2004) Differential susceptibilities of murine hepatoma 1c1c7 and Tao cells to the lysosomal photosensitizer NPe6: influence of aryl hydrocarbon receptor on lysosomal fragility and protease contents. Mol. Pharmacol. 65, 1016-1028.
3. Casanovas O, Hicklin DJ, Bergers G, Hanahan D (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8, 299-309.
4. Cegnar M, Premzl A, Zavasnik-Bergant V, Kristl J, Kos J (2004) Poly (lactide-co-glycolide) nanoparticles as a carrier system for delivering cysteine protease inhibitor cystatin into tumor cells. Exp. Cell Res. 301, 223-231.
5. Dedieu S, Poussard S, Mazeres G, Grise F, Dargelos E, Cottin P, Brustis JJ (2004) Myoblast migration is regulated by calpain through its involvement in cell attachment and cytoskeletal organization. Exp. Cell Res. 292, 187-200.
6. Dvorak HF (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20, 4368-4380.
7. Fajardo LF, Kwan HH, Kowalski J, Prionas SD, Allison AC (1992) Dual role of tumor necrosis factor-alpha in angiogenesis. Am. J. Pathol. 140, 539-544.
8. Ferrara N, Gerber HP, Lecouter J (2003) The biology of VEGF and its receptors. Nat. Med. 9, 669-676.
9. Foekens JA, Kos J, Peters HA, Krasovec M, Look MP, Cimerman N, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG (1998) Prognostic significance of cathepsins B and L in primary human breast cancer. J. Clin. Oncol. 16, 1013-1021.
10. Guidelines for the Care and Use of Animals (2002) Official Journal Announcing Current Legislation in Poland (Dz. U), 135, 1141.
11. Hayrabedyan S, Kyurkchiev S, Kehayov I (2005) FGF-1 and S100A13 possibly contribute to angiogenesis in endometriosis. J. Reprod. Immunol. 67, 87-101.
12. Herszenyi L, Plebani M, Carraro P, De Paoli M, Roveroni G, Cardin R, Foschia F, Tulassay Z, Naccarato R, Farinati F (2000) Proteases in gastrointestinal neoplastic diseases. Clin. Chim. Acta 291, 171-187.
13. Huang Z (2005) A review of progress in clinical photodynamic therapy. Technol. Cancer Res. Treat. 4, 283-293.
14. Joyce JA, Baruch A, Chehade K, Meyer-Morse N, Giraudo E, Tsai FY, Greenbaum DC, Hager JH, Bogyo M, Hanahan D (2004) Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 5, 443-453.
15. Keppler D (2005) Towards novel anti-cancer strategies based on cystatin function. Cancer Lett 235, 159-176.
16. Kopitz C, Anton M, Gansbacher B, Kruger A (2005) Reduction of experimental human fibrosarcoma lung metastasis in mice by adenovirus-mediated cystatin C overexpression in the host. Cancer Res. 65, 8608-8612.
17. Lah TT, Kos J (1998) Cysteine proteinases in cancer progression and their clinical relevance for prognosis. Biol. Chem. 379, 125-130.
18. Lah TT, Kos J, Blejec A, Frkovic-Georgio S, Golouh R, Vrhovec II, Turk VV (1997) The expression of lysosomal proteinases and their inhibitors in breast cancer: possible relationship to prognosis of the disease. Pathol. Oncol. Res. 3, 89-99.
19. Li W, Ding F, Zhang L, Liu Z, Wu Y, Luo A, Wu M, Wang M, Zhan Q (2005) Overexpression of stefin A in human esophageal squamous cell carcinoma cells inhibits tumor cell growth, angiogenesis, invasion, and metastasis. Clin. Cancer Res. 11, 8753-8762.
20. Liu C, Sun C, Huang H, Janda K, Edgington T (2003) Overexpression of legumain in tumors is significant for invasion/ metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res. 63, 2957-2964.
21. Nyberg P, Xie L, Kalluri R (2005) Endogenous inhibitors of angiogenesis. Cancer Res. 65, 3967-3979.
22. Osiecka BJ, Ziolkowski P, Gamian E, Lis-Nawara A, White SG, Bonnett R (2003) Determination of vascular-endothelial growth factor levels in serum from tumor-bearing BALB/c mice treated with photodynamic therapy. Med. Sci. Monit. 9, BR110-BR114.
23. Peng Q, Nesland JM (2004) Effects of photodynamic therapy on tumor stroma. Ultrastruct. Pathol. 28, 333-340.
24. Plaetzer K, Kiesslich T, Oberdanner CB, Krammer B (2005) Apoptosis following photodynamic tumor therapy: induction, mechanisms and detection. Curr. Pharm. Des. 11, 1151-1165.
25. Raynaud F, Carnac G, Marcilhac A, Benyamin Y (2004) m-Calpain implication in cell cycle during muscle precursor cell activation. Exp. Cell Res. 298, 48-57.
26. Reiners JJ Jr, Caruso JA, Mathieu P, Chelladurai B, Yin XM, Kessel D (2002) Release of cytochrome c and activation of pro-caspase-9 following lysosomal photodamage involves bid cleavage. Cell Death Differ. 9, 934-944.
27. Ris HB (2005) Photodynamic therapy as an adjunct to surgery for malignant pleural mesothelioma. Lung Cancer 49 (Suppl. 1), S65-S68.
28. Saleh Y, Siewinski M, Kielan W, Ziolkowski P, Grybos M, Rybka J (2003) Regulation of cathepsin B and L expression in vitro in gastric cancer tissues by egg cystatin. J. Exp. Ther. Oncol. 3, 319-324.
29. Saleh Y, Ziolkowski P, Siewinski M, Milach J, Marszalik P, Rybka J (2001) The combined treatment of transplantable solid mammary carcinoma in Wistar rats by use of photodynamic therapy and cysteine proteinase inhibitor. In Vivo 15, 351-357.
30. Sibata CH, Colussi VC, Oleinick NL, Kinsella TJ (2000) Photodynamic therapy: a new concept in medical treatment. Braz. J. Med. Biol. Res. 33, 869-880.
31. Sokol JP, Neil JR, Schiemann BJ, Schiemann WP (2005) The use of cystatin C to inhibit epithelial-mesenchymal transition and morphological transformation stimulated by transforming growth factor-beta. Breast Cancer Res. 7, R844-R853.
32. Togashi H, Uehara M, Ikeda H, Inokuchi T (2006) Fractionated photodynamic therapy for a human oral squamous cell carcinoma xenograft. Oral Oncol. 45, 526-532.
33. Wey JS, Stoeltzing O, Ellis LM (2004) Vascular endothelial growth factor receptors: expression and function in solid tumors. Clin. Adv. Hematol. Oncol. 2, 37-45.
34. Ziolkowski P, Symonowicz K, Milach J (1996) In vivo interleukin-1-alpha induction following chlorin e6 photodynamic therapy in BALB/c mice. Proc. SPIE 2625, 426-433.
35. Ziolkowski P, Symonowicz K, Milach J, Zawirska B, Szkudlarek T (1997) In vivo tumor necrosis factor-alpha induction following chlorin e6-photodynamic therapy in Buffalo rats. Neoplasma 44, 192-196.
36. Ziolkowski P, Symonowicz K, Osiecka BJ, Rabczynski J, Gerber J (1999) Photodynamic treatment of epithelial tissue derived from patients with endometrial cancer: a contribution to the role of laminin and epidermal growth factor receptor in photodynamic therapy. J. Biomed. Opt. 4, 272-275.